ReNeuron explained

ReNeuron is a UK-based stem cell research company whose shares were listed on the Alternative Investment Market, until it delisted in August 2024 after entering administration.^[1] Its focus is on the development of stem-cell therapies targeting areas of poorly-met medical need, including peripheral arterial disease, strokes, and retinal diseases.

As of 2010 ReNeuron was testing the effects of neural stem cells on spinal cords for neuroregeneration.^[2] They were also testing the use of fetal stem cells on stroke patients.^[3]

Notes and References

1. https://www.msn.com/en-gb/money/other/life-sciences-firm-reneuron-to-delist-as-it-aims-to-exit-administration/ar-AA1pHHpQ Life sciences firm ReNeuron to delist as it aims to exit administration
2. News: Cookson . Clive . Regenerative medicine: Possibilities multiply for nerve cell regrowth . 23 May 2010. 4 May 2010.
3. News: EU agency prepares to assess first stem cell drug. 23 May 2010. Reuters. 12 May 2010.